134 related articles for article (PubMed ID: 38012986)
21. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
Yi L; Fan J; Qian R; Luo P; Zhang J
Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
[TBL] [Abstract][Full Text] [Related]
22. Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis.
Huang L; Huang H; Zhou XP; Liu JF; Li CR; Fang M; Wu JR
Medicine (Baltimore); 2019 Oct; 98(43):e17705. PubMed ID: 31651902
[TBL] [Abstract][Full Text] [Related]
23. Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer.
Xie Y; Lu Q; Wang JQ; Bo L; Ashby CR; Chen ZS
Drugs Today (Barc); 2022 Aug; 58(8):389-398. PubMed ID: 35983925
[TBL] [Abstract][Full Text] [Related]
24. Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.
Luo YH; Liu H; Wampfler JA; Tazelaar HD; Li Y; Peikert T; Liu D; Leventakos K; Chen YM; Yang Y; Chiou SH; Yang P
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2099-2114. PubMed ID: 34436667
[TBL] [Abstract][Full Text] [Related]
25. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
Nassar AH; Kim SY; Aredo JV; Feng J; Shepherd F; Xu C; Kaldas D; Gray JE; Dilling TJ; Neal JW; Wakelee HA; Liu Y; Lin SH; Abuali T; Amini A; Nie Y; Patil T; Lobachov A; Bar J; Fitzgerald B; Fujiwara Y; Marron TU; Thummalapalli R; Yu H; Owen DH; Sharp J; Farid S; Rocha P; Arriola E; D'Aiello A; Cheng H; Whitaker R; Parikh K; Ashara Y; Chen L; Sankar K; Harris JP; Nagasaka M; Ayanambakkam A; Velazquez AI; Ragavan M; Lin JJ; Piotrowska Z; Wilgucki M; Reuss J; Luders H; Grohe C; Baena Espinar J; Feiner E; Punekar SR; Gupta S; Leal T; Kwiatkowski DJ; Mak RH; Adib E; Naqash AR; Goldberg SB
J Thorac Oncol; 2024 Jun; 19(6):928-940. PubMed ID: 38278303
[TBL] [Abstract][Full Text] [Related]
26. Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated
Kim TM; Girard N; Leighl NB; Sabari J; Rahhali N; Schioppa CA; Diels J; Sermon J; Chandler C; Kapetanakis V; Jain R; Li T; Sanden SV
Future Oncol; 2024 Mar; 20(8):447-458. PubMed ID: 37882460
[No Abstract] [Full Text] [Related]
27. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of
Yun J; Lee SH; Kim SY; Jeong SY; Kim JH; Pyo KH; Park CW; Heo SG; Yun MR; Lim S; Lim SM; Hong MH; Kim HR; Thayu M; Curtin JC; Knoblauch RE; Lorenzi MV; Roshak A; Cho BC
Cancer Discov; 2020 Aug; 10(8):1194-1209. PubMed ID: 32414908
[No Abstract] [Full Text] [Related]
28. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
[TBL] [Abstract][Full Text] [Related]
29. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
Cho JH; Lim SH; An HJ; Kim KH; Park KU; Kang EJ; Choi YH; Ahn MS; Lee MH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Clin Oncol; 2020 Feb; 38(5):488-495. PubMed ID: 31825714
[TBL] [Abstract][Full Text] [Related]
30. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Park K; Haura EB; Leighl NB; Mitchell P; Shu CA; Girard N; Viteri S; Han JY; Kim SW; Lee CK; Sabari JK; Spira AI; Yang TY; Kim DW; Lee KH; Sanborn RE; Trigo J; Goto K; Lee JS; Yang JC; Govindan R; Bauml JM; Garrido P; Krebs MG; Reckamp KL; Xie J; Curtin JC; Haddish-Berhane N; Roshak A; Millington D; Lorenzini P; Thayu M; Knoblauch RE; Cho BC
J Clin Oncol; 2021 Oct; 39(30):3391-3402. PubMed ID: 34339292
[TBL] [Abstract][Full Text] [Related]
31. Amivantamab for the treatment of
Vyse S; Huang PH
Expert Rev Anticancer Ther; 2022 Jan; 22(1):3-16. PubMed ID: 34913823
[TBL] [Abstract][Full Text] [Related]
32. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
[TBL] [Abstract][Full Text] [Related]
33. Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial.
Nakashima K; Ozawa Y; Daga H; Imai H; Tamiya M; Tokito T; Kawamura T; Akamatsu H; Tsuboguchi Y; Takahashi T; Yamamoto N; Mori K; Murakami H
Invest New Drugs; 2020 Dec; 38(6):1854-1861. PubMed ID: 32424780
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.
Zhou B; Gong Q; Li B; Qie HL; Li W; Jiang HT; Li HF
J Clin Pharm Ther; 2022 May; 47(5):643-651. PubMed ID: 35023208
[TBL] [Abstract][Full Text] [Related]
35. Overall Survival with Osimertinib in Untreated,
Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
[TBL] [Abstract][Full Text] [Related]
36. Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib.
Yamamoto N; Mera T; Märten A; Hochmair MJ
Adv Ther; 2020 Feb; 37(2):759-769. PubMed ID: 31863283
[TBL] [Abstract][Full Text] [Related]
37. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
38. The development of amivantamab for the treatment of non-small cell lung cancer.
Brazel D; Nagasaka M
Respir Res; 2023 Oct; 24(1):256. PubMed ID: 37880647
[TBL] [Abstract][Full Text] [Related]
39. Osimertinib for
Xie L; Nagpal S; Wakelee HA; Li G; Soltys SG; Neal JW
Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
[TBL] [Abstract][Full Text] [Related]
40. Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis.
Cho BC; Kim DW; Park K; Lee JS; Yoo SS; Kang JH; Lee SY; Kim CH; Jang SH; Kim YC; Yoon HK; Han JY; Kim SW
Curr Med Res Opin; 2020 Mar; 36(3):477-482. PubMed ID: 31581843
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
